Synergistic apoptosis of MCF-7 breast cancer cells by 2-methoxyestradiol and bis(ethyl)norspermine.

[1]  Ting-Chao Chou,et al.  Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies , 2006, Pharmacological Reviews.

[2]  J. Yodoi,et al.  17β-Estradiol Protects against Oxidative Stress-induced Cell Death through the Glutathione/Glutaredoxin-dependent Redox Regulation of Akt in Myocardiac H9c2 Cells* , 2006, Journal of Biological Chemistry.

[3]  A. Verma,et al.  Physiologic Levels of 2-Methoxyestradiol Interfere with Nongenomic Signaling of 17β-Estradiol in Human Breast Cancer Cells , 2006, Clinical Cancer Research.

[4]  Sushanta K Banerjee,et al.  Modulation of cell-cycle regulatory signaling network by 2-methoxyestradiol in prostate cancer cells is mediated through multiple signal transduction pathways. , 2006, Biochemistry.

[5]  E. Ariazi,et al.  Estrogen receptors as therapeutic targets in breast cancer. , 2006, Current topics in medicinal chemistry.

[6]  E. Tokunaga,et al.  Akt is frequently activated in HER2/neu‐positive breast cancers and associated with poor prognosis among hormone‐treated patients , 2006, International journal of cancer.

[7]  Zhe Zhang,et al.  Spermine Oxidase SMO(PAOh1), Not N1-Acetylpolyamine Oxidase PAO, Is the Primary Source of Cytotoxic H2O2 in Polyamine Analogue-treated Human Breast Cancer Cell Lines* , 2005, Journal of Biological Chemistry.

[8]  G. Sledge,et al.  beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. , 2005, Cancer research.

[9]  C. Yiannoutsos,et al.  A Phase II Multicenter, Randomized, Double-Blind, Safety Trial Assessing the Pharmacokinetics, Pharmacodynamics, and Efficacy of Oral 2-Methoxyestradiol Capsules in Hormone-Refractory Prostate Cancer , 2005, Clinical Cancer Research.

[10]  J. Pollard,et al.  Progesterone inhibits the estrogen-induced phosphoinositide 3-kinase-->AKT-->GSK-3beta-->cyclin D1-->pRB pathway to block uterine epithelial cell proliferation. , 2005, Molecular endocrinology.

[11]  P. Dent,et al.  2-Methoxyestradiol-induced apoptosis in human leukemia cells proceeds through a reactive oxygen species and Akt-dependent process , 2005, Oncogene.

[12]  M. Hung,et al.  Signaling intricacies take center stage in cancer cells. , 2005, Cancer research.

[13]  N. Davidson,et al.  Molecular mechanisms of polyamine analogs in cancer cells. , 2005, Anti-cancer drugs.

[14]  T. Thomas,et al.  Differential effects of 16α-hydroxyestrone and 2-methoxyestradiol on cyclin D1 involving the transcription factor ATF-2 in MCF-7 breast cancer cells , 2005 .

[15]  B. Zhu,et al.  Synergism between the anticancer actions of 2-methoxyestradiol and microtubule-disrupting agents in human breast cancer. , 2005, Cancer research.

[16]  C. Van Waes,et al.  2-Methoxyestradiol Inhibits Hypoxia-Inducible Factor 1α, Tumor Growth, and Angiogenesis and Augments Paclitaxel Efficacy in Head and Neck Squamous Cell Carcinoma , 2004, Clinical Cancer Research.

[17]  C. Thompson,et al.  Putting the rap on Akt. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  E. Gerner,et al.  Polyamines and cancer: old molecules, new understanding , 2004, Nature Reviews Cancer.

[19]  M. Gallo,et al.  Estrogen receptors as targets for drug development for breast cancer, osteoporosis and cardiovascular diseases. , 2004, Current cancer drug targets.

[20]  J. Wimalasena,et al.  Estradiol abrogates apoptosis in breast cancer cells through inactivation of BAD: Ras-dependent nongenomic pathways requiring signaling through ERK and Akt. , 2004, Molecular biology of the cell.

[21]  B. Zhu,et al.  Concentration-dependent mitogenic and antiproliferative actions of 2-methoxyestradiol in estrogen receptor-positive human breast cancer cells , 2004, The Journal of Steroid Biochemistry and Molecular Biology.

[22]  F. Mollinedo,et al.  Microtubules, microtubule-interfering agents and apoptosis , 2003, Apoptosis.

[23]  T. Thomas,et al.  Estradiol control of ornithine decarboxylase mRNA, enzyme activity, and polyamine levels in MCF-7 breast cancer cells: therapeutic implications , 2004, Breast Cancer Research and Treatment.

[24]  A. Wolff,et al.  A Phase II study of the polyamine analog N1,N11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[25]  S. Mooberry.  New insights into 2-methoxyestradiol, a promising antiangiogenic and antitumor agent , 2003, Current opinion in oncology.

[26]  J. Russo,et al.  Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells , 2003, The Journal of Steroid Biochemistry and Molecular Biology.

[27]  H. Hanafusa,et al.  PTEN Induces Cell Cycle Arrest by Decreasing the Level and Nuclear Localization of Cyclin D1 , 2003, Molecular and Cellular Biology.

[28]  W. Wong,et al.  Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. , 2003, Blood.

[29]  W. Figg,et al.  2‐Methoxyestradiol, a Promising Anticancer Agent , 2003, Pharmacotherapy.

[30]  X. Shu,et al.  Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre- versus post-treatment collection , 2003, Steroids.

[31]  Olle Stål,et al.  Akt kinases in breast cancer and the results of adjuvant therapy , 2003, Breast Cancer Research.

[32]  M. Gallo,et al.  Development of polyamine analogs as cancer therapeutic agents. , 2002, Oncology research.

[33]  S. Kaufmann,et al.  G1 and G2 cell-cycle arrest following microtubule depolymerization in human breast cancer cells , 2002 .

[34]  P. Dennis,et al.  Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.

[35]  D. Ettinger,et al.  Phase I study of N(1),N(11)-diethylnorspermine in patients with non-small cell lung cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[36]  S. Kaufmann,et al.  G(1) and G(2) cell-cycle arrest following microtubule depolymerization in human breast cancer cells. , 2002, The Journal of clinical investigation.

[37]  M. Wozniak,et al.  Dual effect of 2-methoxyestradiol on cell cycle events in human osteosarcoma 143B cells. , 2002, Acta biochimica Polonica.

[38]  D E Ingber,et al.  Cooperative control of Akt phosphorylation, bcl-2 expression, and apoptosis by cytoskeletal microfilaments and microtubules in capillary endothelial cells. , 2001, Molecular biology of the cell.

[39]  J E Paciga,et al.  Phosphatidylinositol-3-OH Kinase (PI3K)/AKT2, activated in breast cancer, regulates and is induced by estrogen receptor alpha (ERalpha) via interaction between ERalpha and PI3K. , 2001, Cancer research.

[40]  A. Conney,et al.  Characterization of the NADPH-dependent metabolism of 17beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5. , 2001, The Journal of pharmacology and experimental therapeutics.

[41]  E. Nogales.  Structural insight into microtubule function. , 2001, Annual review of biophysics and biomolecular structure.

[42]  Simak Ali,et al.  Phosphatidylinositol 3-Kinase/AKT-mediated Activation of Estrogen Receptor α , 2001, The Journal of Biological Chemistry.

[43]  Peng Huang,et al.  Superoxide dismutase as a target for the selective killing of cancer cells , 2000, Nature.

[44]  L. Skoog,et al.  Expression of Akt kinases related to ErbB2 and results of adjuvant therapy of breast cancer , 2000, Breast Cancer Research.

[45]  X. Shu,et al.  Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. , 2000, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[46]  J. Díaz,et al.  Prognostic value of ornithine decarboxylase and polyamines in human breast cancer: correlation with clinicopathologic parameters. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  D. Kramer,et al.  Polyamine analogue induction of the p53-p21WAF1/CIP1-Rb pathway and G1 arrest in human melanoma cells. , 1999, Cancer research.

[48]  J. Wolff.  Promotion of microtubule assembly by oligocations: cooperativity between charged groups. , 1998, Biochemistry.

[49]  A. Conney,et al.  Is 2-methoxyestradiol an endogenous estrogen metabolite that inhibits mammary carcinogenesis? , 1998, Cancer research.

[50]  J. Liehr,et al.  4-Hydroxylation of estradiol by human uterine myometrium and myoma microsomes: implications for the mechanism of uterine tumorigenesis. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  R. Bergeron,et al.  Preclinical antitumor efficacy of the polyamine analogue N1, N11-diethylnorspermine administered by multiple injection or continuous infusion. , 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

[52]  R. Motzer,et al.  Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design. , 1994, Journal of the National Cancer Institute.

[53]  M. Dolan,et al.  Effect of 1,19-bis(ethylamino)-5,10,15-triazanonadecane on human tumor xenografts. , 1994, Cancer research.

[54]  R. D'Amato,et al.  2-Methoxyestradiol, an endogenous mammalian metabolite, inhibits tubulin polymerization by interacting at the colchicine site. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[55]  Michael S. Pepper,et al.  The endogenous oestrogen metabolite 2-methoxyoestradiol inhibits angiogenesis and suppresses tumour growth , 1994, Nature.

[56]  T. Chou,et al.  Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. , 1984, Advances in enzyme regulation.

[57]  E. Kuss,et al.  Concentrations of 2-methoxyoestrogens in human serum measured by a heterologous immunoassay with an 125I-labelled ligand. , 1982, Acta endocrinologica.